MaxCyte (MXCT) | Stock Overview & Key Data

What is MXCT's 52-week high and low?

In the last 52 weeks, MaxCyte reached a high of $5.20 (on January 21, 2025) and a low of $2.00 (on June 25, 2025).

What is the market cap and P/E ratio for MXCT?

Curious about MaxCyte's size and valuation? Its market capitalization stands at 230.71M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.68, and the forward P/E (looking ahead) is -5.56.

Does MXCT pay dividends? If so, what's the yield?

As for dividends, MaxCyte isn't currently offering a significant yield, or that specific data isn't available right now.

Who are MaxCyte's main competitors or similar companies to consider before investing?

When looking at MaxCyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Abbott Laboratories ABT	231.85B	Healthcare	Medical Devices	29.24%	23.05%
Boston Scientific BSX	149.87B	Healthcare	Medical Devices	36.54%	175.69%
908 Devices MASS	238.12M	Healthcare	Medical Devices	40.30%	-68.06%
Tactile Systems TCMD	236.44M	Healthcare	Medical Devices	-10.27%	30.71%
Perspective CATX	256.83M	Healthcare	Medical Devices	-65.67%	18.71%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for MaxCyte Inc.? (e.g., ROE, Debt/Equity)

To get a sense of MaxCyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -19.63%, the Debt to Equity ratio from the most recent quarter is 9.44, and its Gross Profit Margin stands at 85.59%.

What is the recent revenue and earnings growth for MXCT?

Looking at MaxCyte's growth, its revenue over the trailing twelve months (TTM) was $38M. Compared to the same quarter last year (YoY), quarterly revenue grew by -8.40%, and quarterly earnings saw a YoY growth of -8.39%.

How much of MXCT stock is held by insiders and institutions?

Wondering who owns MaxCyte stock? Company insiders (like executives and directors) hold about 1.23% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 75.99%.

For more common questions about our data, please visit our About Data page.